NUCANA PLC-ADR (NCNA)
US67022C1062 - ADR
NUCANA PLC-ADR
NASDAQ:NCNA (4/16/2024, 12:01:06 PM)
3.9
+3.72 (+2066.67%)
Company Profile
NuCana Plc is a clinical stage biopharmaceutical company. The firm is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The firm's pipeline includes NUC-3373, and NUC-7738. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil (5-FU). 5-FU is a prescribed anti-cancer agent. NUC-3373 has been evaluated in a Phase I clinical trial for patients with advanced solid tumors and is under Phase Ib/II clinical trial for patients with advanced colorectal cancer. NUC-7738 is a ProTide transformation of a nucleoside analog, 3’-deoxyadenosine (3’-Da). The firm is evaluating NUC-7738 in a Phase I/II clinical trial for patients with advanced solid tumors. Its pipeline also includes Acelari. The Company’s subsidiaries include NuCana, Inc., NuCana Limited and NuCana BioMed Trustee Company Limited.
Company Info
NUCANA PLC-ADR
Lochside House, 3 Lochside Way
Edinburgh EH12 9DT
P: 4401313571111
CEO: Hugh Griffith
Employees: 28
Website: https://www.nucana.com/
NCNA News
an hour ago - ChartmillHere are the top movers in Tuesday's session, showcasing the stocks with significant price changes.Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.
3 hours ago - ChartmillThere are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Tuesday.Let's have a look at the gap up and gap down stocks in today's session.
5 hours ago - NuCana plcNuCana Announces Completion of ADS Ratio Change7 days ago - NuCana plcNuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumor Biology in a Paired Biopsy Clinical Study
7 days ago - NuCana plcNuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumor Biology in a Paired Biopsy Clinical StudyNUC-7738 Reprograms Cancer Cell Lipid Metabolism to Make Tumors Less Aggressive and Promote Cancer Cell Death NUC-7738 Alters Ribosome Biogenesis and the...
12 days ago - ChartmillStay updated with the stocks that are on the move in today's pre-market session.Before the US market kicks off on Thursday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.
NCNA Twits
Here you can normally see the latest stock twits on NCNA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
